Condition (MeSH)
Synovitis
ClinicalTrials.gov lists 80 trials for Synovitis or a narrower condition beneath it. Daiichi Sankyo has the most among industry and government lead sponsors, with 6.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
52 of the 80 trials are tagged with Synovitis itself; the rest are tagged with a narrower condition beneath it.
When did Synovitis trials start? (24)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 6 |
| 2025 | 5 |
| 2024 | 4 |
| 2023 | 5 |
| 2022 | 3 |
| 2021 | 6 |
| 2020 | 6 |
| 2019 | 1 |
| 2018 | 4 |
| 2017 | 1 |
Showing 10 of 24 earlier years.
No forecast is made for this condition: it averages 4.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 23 months across 46 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Synovitis trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 7 |
| Phase 1/2 | 2 |
| Phase 2 | 16 |
| Phase 3 | 8 |
| Phase 4 | 6 |
| Not applicable | 13 |
| Observational | 28 |
How many Synovitis trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 5 |
| Recruiting | 13 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 7 |
| Completed | 39 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Synovitis trials? (10)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Daiichi Sankyo | 6 |
| National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 5 |
| AmMax Bio, Inc. | 3 |
| Deciphera Pharmaceuticals, LLC | 3 |
| Abbisko Therapeutics Co, Ltd | 2 |
Showing 5 of 10 sponsors.
Which drugs are being tested for Synovitis? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Pexidartinib | 6 |
| Pimicotinib | 4 |
| Vimseltinib | 3 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| HD- Methotrexate (MTX) | 4 |
| AMB-05X | 3 |
| Nilotinib Pill | 2 |
| MRI | 2 |
| Capsaicin, USP 0.0375% | 1 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Synovitis trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Abdominal pain | 4 | 2 |
| Cellulitis | 4 | 1 |
| Migraine | 4 | 2 |
| Blood bilirubin increased | 3 | 1 |
| FALL | 3 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Synovitis? (253)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Immunophenotyping of Synovial Tissue in Adolescents Undergoing ACL Reconstruction: What Is the Role of Synovial Inflammation in Arthrofibrosis? | The American journal of sports medicine | 2025 | Yes |
| Effective Treatment of Janus Kinase 1/3 Inhibitor in Blau Syndrome From a Multicenter Retrospective Study in Central China. | The Journal of rheumatology | 2025 | Yes |
| Low-Dose Methotrexate for the Treatment of Inflammatory Knee Osteoarthritis: A Randomized Clinical Trial. | JAMA internal medicine | 2025 | Yes |
| Safety and Efficacy of Radiosynoviorthesis: A Prospective Canadian Multicenter Study. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine | 2024 | Yes |
| Correspondence on 'Glucosamine and O-GlcNAcylation: a novel immunometabolic therapeutic target for OA and chronic, low-grade systemic inflammation?' | Annals of the rheumatic diseases | 2023 | Yes |
Showing 5 of 253 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.